Novadaq Technologies

What Novadaq Technologies does

Novadaq Technologies was a medical technology company headquartered in Kalamazoo, Michigan, that developed fluorescence imaging systems for surgical applications. The company's core technology enabled real-time intraoperative visualization of tissue perfusion and blood flow, allowing surgeons performing minimally invasive procedures to assess tissue viability during operations. Its principal commercial products included the SPY Elite and SPY PHI Fluorescence Imaging Systems, which were sold to hospitals and surgical centers as capital equipment integrated into operating room workflows.

The company operated a horizontal go-to-market targeting medical facilities and healthcare providers, with sales driven by clinical adoption among surgical specialties. Novadaq expanded its platform through M&A, acquiring Xillix in 2007 and Aïmago in 2014 for $12.4 million, broadening its fluorescence imaging capabilities. The company reached commercial-stage status and was publicly traded on NASDAQ under ticker NVDQ before being acquired by Stryker Corporation in 2017 for $700 million. Following the acquisition, Novadaq's technology was integrated into Stryker's Endoscopy business unit within its surgical visualization portfolio, and the company ceased operating as an independent entity.

Name

Novadaq Technologies

Legal name

Novadaq Technologies

Website

https://novadaq.com

Company type

Private

Founded year

2000

Operating status

Acquired

Headcount range

501–1,000 employees

Short description

Novadaq Technologies developed fluorescence imaging systems (SPY Elite, SPY PHI) for real-time intraoperative visualization of tissue perfusion and blood flow, serving hospitals and surgical centers. Acquired by Stryker in 2017 for $700M.

Ownership category

akta.pro rank

Product category

Surgical Visualization & Fluorescence Imaging

NAICS

Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)

akta.pro primary industry

Intraoperative Imaging & Guidance (C-arms, O-arm, IOUS, fluorescence) (HLAHADAH)

akta.pro secondary industries

Surgical Visualization & OR Video Integration (4K/3D, Recording, Routing) (HLAHADAD), Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB), Interventional Radiology & Image-Guided Therapy Systems (HLAHABAG)

Keywords

• Fluorescence imaging systems
• Surgical visualization
• Intraoperative imaging
• Medical imaging devices
• Tissue perfusion imaging

Headquarters

HQ city

Kalamazoo

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Supply Chain

Core offering

Novadaq Technologies developed and commercialized clinically-relevant fluorescence imaging solutions — including the SPY Elite and SPY PHI systems — that enabled surgeons to visualize tissue perfusion, blood flow, and tissue viability in real time during open and minimally invasive procedures in the operating room and clinic. The company also performed tuck-in acquisitions of complementary imaging businesses (Xillix in 2007, Aïmago in 2014).

Product overview

Novadaq Technologies was a privately held medical technology company specializing in fluorescence imaging technology for surgical applications. The company was acquired by Stryker Corporation in 2017 for $700 million. Following the acquisition, Novadaq's technology became part of Stryker's surgical visualization portfolio. The source data does not contain first-party Novadaq product documentation or website content from which specific product details could be extracted.

Differentiator

Problem solved

Functional benefit

Products and services

• SPY Elite Fluorescence Imaging System Fluorescence imaging platform that enables surgeons to visualize tissue perfusion and blood flow in real time during open and minimally invasive surgical procedures in the operating room.
• SPY PHI Fluorescence Imaging System Companion fluorescence imaging system to SPY Elite, providing intraoperative visualization of perfusion and tissue viability for surgical applications across the operating room and clinic.

Quantifiable outcome

• Achieved commercial-stage exit valued at $700 million

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• StrykermajorStrategic or Co-development Partner · 1 January 2017Stryker Corporation acquired Novadaq Technologies for $700 million in 2017. This commercial-stage acquisition was cited as an example of successful medtech exits, significantly outperforming pre-commercial exits. The acquisition expanded Stryker's surgical visualization portfolio.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• Intuitive Surgical: Da Vinci platform with Firefly fluorescence imaging integrates ICG-based intraoperative visualization into robotic surgery — the most direct modality competitor to Novadaq's SPY in minimally invasive procedures.
• Karl Storz: Endoscopy and surgical visualization incumbent offering ICG/near-infrared fluorescence imaging modules (e.g., IMAGE1 S, NIR/ICG modes) that compete head-to-head with SPY in laparoscopic and open surgery.
• Olympus: Major surgical visualization platform (VISERA, ORBEYE 4K 3D) with NBI and IR fluorescence imaging options, competing for the same intraoperative visualization use cases that SPY addresses.
• Carl Zeiss Meditec: Surgical microscopy and visualization (e.g., OPMI Pentero, Kinevo) used in neurosurgery, ENT, and ophthalmology; provides intraoperative optical imaging capabilities overlapping with SPY's clinical role.
• Leica Microsystems (Danaher): Surgical microscopy platform (e.g., M530 OHX, ARveo) with fluorescence imaging modes for neurosurgical and intraoperative use — direct overlap with Novadaq's fluorescence-guided surgery niche.

Broad incumbents

• Medtronic: Diversified medtech incumbent with surgical visualization and imaging offerings (e.g., StealthStation, surgical endoscopy) that compete for OR capital and procedure-utility share against SPY.
• Getinge (Maquet): OR integration and surgical equipment provider (lights, tables, surgical workplace) competing in the integrated OR where SPY-class visualization systems are installed and sold.
• Stryker: Acquirer of Novadaq and the parent company that now owns and distributes the SPY platform as part of its surgical visualization and endoscopy portfolio. Directly comparable as the strategic home for Novadaq's technology.

Emerging players

• Hamamatsu Photonics: Developer of optoelectronic imaging components and ICG-compatible camera/sensor technology used in fluorescence imaging systems — comparable as an enabling/adjacent technology supplier to SPY-class platforms.
• Conmed: General surgery and visualization portfolio (airSeal, hand instruments) that overlaps with the broader surgical visualization workflow where SPY is deployed in laparoscopic and robotic procedures.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/novadaqtech
• LinkedInlinkedin.com/company/105693

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novadaq Technologies